Benchmark set a $10.00 price objective on Harvard Bioscience (NASDAQ:HBIO) in a research report released on Monday. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Other research analysts have also issued research reports about the company. Zacks Investment Research raised Harvard Bioscience from a hold rating to a buy rating and set a $5.25 price objective on the stock in a report on Thursday, March 8th. Janney Montgomery Scott raised their target price on Harvard Bioscience from $5.00 to $8.00 and gave the company a buy rating in a report on Wednesday, January 24th. Finally, ValuEngine raised Harvard Bioscience from a hold rating to a buy rating in a report on Monday, April 2nd. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Harvard Bioscience presently has an average rating of Buy and a consensus price target of $7.75.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ HBIO opened at $5.85 on Monday. The company has a current ratio of 3.39, a quick ratio of 1.86 and a debt-to-equity ratio of 0.11. The stock has a market cap of $199.38, a PE ratio of 93.33 and a beta of 1.27. Harvard Bioscience has a 52 week low of $2.30 and a 52 week high of $6.00.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, March 1st. The medical instruments supplier reported $0.05 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.05. The business had revenue of $27.46 million for the quarter, compared to analyst estimates of $26.60 million. Harvard Bioscience had a positive return on equity of 2.34% and a negative net margin of 0.85%. research analysts expect that Harvard Bioscience will post 0.12 earnings per share for the current year.

In other Harvard Bioscience news, CEO Jeffrey Duchemin sold 87,022 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $4.53, for a total value of $394,209.66. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George Uveges sold 22,250 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $4.58, for a total value of $101,905.00. The disclosure for this sale can be found here. Insiders sold a total of 241,413 shares of company stock worth $1,106,256 in the last ninety days. Insiders own 7.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HBIO. Wells Fargo & Company MN grew its holdings in Harvard Bioscience by 2,013.7% in the 4th quarter. Wells Fargo & Company MN now owns 32,446 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 30,911 shares during the last quarter. Northern Trust Corp grew its holdings in Harvard Bioscience by 5.2% in the 2nd quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after buying an additional 4,260 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Harvard Bioscience in the 3rd quarter valued at approximately $321,000. AXA grew its holdings in Harvard Bioscience by 16.7% in the 4th quarter. AXA now owns 167,500 shares of the medical instruments supplier’s stock valued at $553,000 after buying an additional 24,000 shares during the last quarter. Finally, Algert Global LLC grew its holdings in Harvard Bioscience by 31.0% in the 3rd quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after buying an additional 35,276 shares during the last quarter. 62.25% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/04/17/benchmark-analysts-give-harvard-bioscience-hbio-a-10-00-price-target.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.